Compile Data Set for Download or QSAR
maximum 50k data
Found 27 Enz. Inhib. hit(s) with all data for entry = 10075
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512297(US11084821, Example 26 | rac-(4aR,7aS)-4-(4-Cyano-...)
Affinity DataIC50:  5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512295(US11084821, Example 24 | rac-(4aR,7aS)-4-(5-(3-Cya...)
Affinity DataIC50:  5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512296(US11084821, Example 25 | rac-(4aR,7aS)-4-(5-(3-Cya...)
Affinity DataIC50:  5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512290(US11084821, Example 19 | cis-4-(2'-Cyano-[3,4'-bip...)
Affinity DataIC50:  5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512294(US11084821, Example 23 | rac-(4aR,7aS)-4-(5-(3-Cya...)
Affinity DataIC50:  5.5nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512291(US11084821, Example 20 | cis-4-(2'-Cyano-[3,4'-bip...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512293(US11084821, Example 22 | cis-4-(6-(2-Cyanopyridin-...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512298(US11084821, Example 27 | rac-(4aR,7aS)-4-(2-Cyano-...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512286((3aR,6aR)-1-(6-(Trifluoromethoxy)-1H-benzo[d]imida...)
Affinity DataIC50:  55nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512289((R)-3-(Methyl(6-(trifluoromethyl)-1H-benzo[d]imida...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512288((3aR,6aR)-1-(6-Methoxy-1H-benzo[d]imidazol-2-yl)he...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512287(2-((3aR,6aR)-5-Cyanohexahydropyrrolo[3,4-b]pyrrol-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512280(US11084821, Example 10 | trans-4-(5-Phenylthiazol-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512279(US11084821, Example 9 | cis-4-(5-Phenylthiazol-2-y...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512278(US11084821, Example 8 | cis-1-(5-Phenylthiazol-2-y...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512277(US11084821, Example 7 | cis-4-(4-Phenylpyrimidin-2...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512276(US11084821, Example 6 | cis-4-(6-Phenylpyridin-2- ...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512275(US11084821, Example 5 | cis-4-(5-Phenylpyridin-2- ...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512272(US11084821, Example 2 | cis-4-(6-Phenylpyridazin-3...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512292(US11084821, Example 21 | cis-4-(6-(2-Cyanopyridin-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM511941(1-Phenylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbo...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512281(1-(5-Phenylthiazol-2-yl)octahydro-6H-pyrrolo[3,4-b...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512274(US11084821, Example 4 | cis-4-(4-Phenylpyridin-2- ...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512273(US11084821, Example 3 | cis-4-(6-Fluorobenzo[d]thi...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512284(3-(Methyl(5-phenylthiazol-2-yl)amino)pyrrolidine-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512285(3-(Methyl(5-phenylpyridin-2-yl)amino)pyrrolidine-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM512282(3-((5-Phenylthiazol-2-yl)amino)pyrrolidine-1-carbo...)
Affinity DataIC50:  2.00E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent